Activation of adenosine receptors has been implicated in several biological functions, including cardiovascular and renal function. Diabetes causes morphological and functional changes in the vasculature, resulting in abnormal responses to various stimuli. Recent studies have suggested that adenosine receptor expression and signaling are altered in disease states such as hypertension, diabetes. Using a streptozotocin (STZ) mouse model of type I diabetes (T1D), we investigated the functional changes in aorta and resistance mesenteric arteries to adenosine receptor agonist activation in T1D. Organ baths and DMT wire myographs were used for muscle tension measurements in isolated vascular rings, and western blotting was used for protein analysis. Concentration response curves to selective adenosine receptor agonists, including CCPA (A 1 receptor agonist), Cl-IBMECA (A 3 receptor agonist), CGS-21680 (A 2A receptor agonist), and BAY 60-6583 (A 2B receptor agonist), were performed. We found that diabetes did not affect adenosine receptor agonist-mediated relaxation or contraction in mesenteric arteries. However, aortas from diabetic mice exhibited a significant decrease (P < 0.05) in A 1 receptor-mediated vasoconstriction. In addition, the aortas from STZ-treated mice exhibited an increase in phenylephrine-mediated contraction (EC 50 7.40 ± 0.08 in STZ vs 6.89 ± 0.14 in vehicle; P < 0.05), while relaxation to A 2A receptor agonists (CGS-21680) tended to decrease in aortas from the STZ-treated group (not statistically significant). Our data suggest that changes in adenosine receptor(s) vascular reactivity in T1D is tissue specific, and the decrease in A 1 receptor-mediated aortic contraction could be a compensatory mechanism to counterbalance the increased adrenergic vascular contractility observed in aortas from diabetic mice.
Introduction
Adenosine is produced during conditions of metabolic stress and high cellular activity to increase oxygen supply and decrease oxygen consumption. Adenosine is mainly generated by the 5′-nucleotidases, which catalyze the dephosphorylation of adenosine monophosphate (AMP) into adenosine. Intracellular adenosine levels are mainly regulated by adenosine kinase, which converts adenosine into AMP, while extracellular adenosine levels are regulated by adenosine deaminase, which degrades adenosine to inosine (Blackburn, 2003; Ham and Evans, 2012; Wen and Xia, 2012) . Adenosine binds to a family of four P1 G-protein coupled receptors; namely A 1 , A 2A , A 2B , and A 3 adenosine receptor. Their activation is implicated in the modulation of renal and cardiovascular function as well as erectile function (Headrick et al., 2013; Labazi et al., 2016b; Layland et al., 2014; Phatarpekar et al., 2010; Vallon and Osswald, 2009; Wen and Xia, 2012) . Recently, adenosine was described as an endothelium-derived hyperpolarizing factor due to its ability to relax and hyperpolarize vascular smooth muscle cells (Ohta et al., 2013) . Vascular studies from our laboratory and others have demonstrated that, while A 1 and A 3 adenosine receptor activation results in vasoconstriction, A 2A and A 2B adenosine receptor activation results in vasodilation (Ansari et al., 2007; El-Awady et al., 2011; El-Gowelli et al., 2013; Hein et al., 2013; Kunduri et al., 2013b; Labazi et al., 2016a Labazi et al., , 2016b Nayeem et al., 2008; Sanjani et al., 2011; Tawfik et al., 2005; Teng et al., 2013) . However, the contribution of each receptor to overall vascular tone regulation can be animal-or tissue-specific. For instance, our laboratory and others demonstrated that adenosine-mediated vasorelaxation in murine mesenteric arteries is A 2B adenosine receptor-dependent (Teng et al., 2013; Wang et al., 2010) , while others showed that adenosine-mediated vasorelaxation in rat and rabbit mesenteric arteries is mainly dependent upon the A 2A adenosine receptor (de Brito et al., 2002; Hiley et al., 1995) .
Type I diabetes (T1D) is a metabolic disease characterized by a deficit in insulin secretion resulting in increased blood glucose levels. In the U.S., a recently published study showed that the prevalence of T1D in youth has increased by 21.1% (Hamman et al., 2014) . Additionally, chronic diabetes causes damage to several organ systems. In the vasculature, the effect of diabetes can be divided into microvascular (retinopathy, nephropathy, and cardiomyopathy) and macrovascular (cardiovascular diseases and erectile dysfunction) complications, with cardiovascular disease being the leading cause of morbidity and mortality in diabetic patients (Shi and Vanhoutte, 2009) . Few studies have reported that cell-and tissue-specific changes in adenosine receptor expression can be altered in disease states such as diabetes (Bender et al., 2009; Duarte et al., 2006; Grden et al., 2005 Grden et al., , 2007 Labazi et al., 2016a; Pawelczyk et al., 2005) . However, not much is known about the changes in adenosine receptor expression and/or signaling in the vasculature. In the present study, we sought to investigate the effect of T1D on adenosine receptor-mediated regulation of vascular tone in the aorta and mesenteric arteries.
Materials and methods

Drugs and solutions
Acetylcholine and phenylephrine, 1-[2- methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide(Cl-IBMECA) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 2-Chloro-N6-cyclopentyladenosine (CCPA) and 2- phenyl]-2-pyridinyl] thio]-acetamide (BAY, Bay 60-6583) were purchased from Tocris Bioscience.
Animals
All experimental protocols were performed according to West Virginia University guidelines and with approval of the Animal Care and Use Committee.
Induction of diabetes
T1D was induced in 7 to 9 week-old C57BL/6 male mice following the protocol of the Animal Models of Diabetic Complications Consortium and using multiple low-dose streptozotocin (STZ; Sigma, St. Louis, MO) injections as previously described (Labazi et al., 2016a; Wu and Huan, 2008) . Briefly, injections of 50 mg/kg body weight STZ dissolved in sodium citrate buffer (pH 4.5) were performed daily for 5 consecutive days after 4-5 h of fasting. Mice that served as vehicle controls were given the same volume per body weight of sodium citrate buffer. Mice with blood glucose levels > 250 mg/dl were considered diabetic. Twelve weeks post-STZ injections, animals were sacrificed for further experimentation (Oelze et al., 2011) .
Functional studies in aortas and mesenteric arteries
Mice were euthanized with sodium pentobarbital (65 mg/kg i.p.) followed by thoracotomy. Thoracic aortas and the intestines were isolated from vehicle-and STZ-treated mice and placed in oxygenated Krebs-Henseleit buffer (pH 7.4) containing (in mM) 118 NaCl, 4.8 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 11 glucose, and 2.5 CaCl 2 and maintained at 37°C with continuous bubbling of 95% O 2 -5% CO 2 (ElAwady et al., 2011; Kunduri et al., 2013a; Ponnoth et al., 2009) .
Thoracic aortas were cleaned from fat and connective tissue then cut transversely into 2-to 3-mm rings. Aortic rings were mounted vertically between two stainless steel wire hooks and suspended in 6-ml organ baths containing Krebs-Henseleit buffer. For measurement of isometric tension, aortic rings were equilibrated for 60 min with a resting force of 1 g. Changes in tension were monitored continuously with a fixed range precision force transducer (TSD, 125 C; Biopac system) connected to a differential amplifier (DA 100B; Biopac system). The data were recorded using an MP100 Biopac digital acquisition system and analyzed using Acknowledge 3.5.7 software (Biopac system) (Ponnoth et al., 2009) . After stabilization, rings were precontracted with 50 mM KCl to check the viability and contractility of individual aortic rings. Endothelial integrity was assessed by contraction with phenylephrine (PE, 10 -6 M), followed by relaxation with acetylcholine (ACh, 10 -6 M). In addition to concentration response curves (CRCs) to PE, CRCs to ACh and adenosine receptor agonists (CCPA, Bay 60-6583 (BAY), CGS21680 [CGS)] and Cl-IBMEC; 10 -10 to 10 -5 M were performed in PE-precontracted vessels.
First-order branches (~200 µm) of the superior mesentery arteries were isolated and cleaned of surrounding tissue. The arterial rings were mounted on an isometric myograph (Danish MyoTechology A/S, Aarhus, Denmark). Each vascular ring was stretched to a resting passive tension (200 mg) and allowed to equilibrate for at least 30 min. Viability of the vascular ring was verified by recording contraction after the addition of 50 mM KCl to the tissue bath. The integrity of the endothelium was confirmed by the addition of the endothelium-dependent vasodilator ACh (10 -6 M) during the plateau phase of 10 -6 M PEinduced contraction (Teng et al., 2013) . CRCs to ACh and adenosine receptors agonists (CCPA, BAY,and Cl-IBMEC; 10 -10 to 10 -5 M) were performed in PE-precontracted vessels.
Protein expression
Western blot analyses were performed as described previously from this laboratory (Kunduri et al., 2013a) . Aortas from vehicle and STZtreated mice were homogenized with 150 μl radio-immuno precipitation assay buffer (Cell Signaling Technology; 20 mM Tris-HCl[pH 7.5],150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , and 1 μg/ml leupeptin), vortexed, and centrifuged for 10 min at 13,800 G at 4°C. Protein was measured using the Bradford dye procedure with bovine serum albumin as a standard (Bio-Rad Laboratories; Hercules, CA). Samples (25-30 μg of total protein) were loaded on slab gels (10% acrylamide; 1 mm thick), separated by SDS-PAGE, and transferred to nitrocellulose membranes (Hybond-ECL). Protein transfer was confirmed by visualization of prestained molecular weight markers (Bio-Rad). Membranes were blocked with 5% nonfat dry milk and incubated with A 1 adenosine receptor primary antibody (1:1000 dilution) (Sigma; St. Louis, MO); β-actin antibody (1:10,000 dilution) (Santa Cruz Biotechnology; Santa Cruz, CA) was used as an internal control to normalize the target protein expression in each lane. Membranes were developed using enhanced chemiluminescence (GE Healthcare) and x-ray film.
Statistical analysis
CRCs were analyzed using analysis of variance (ANOVA) followed by Bonferroni to compare between groups at the same concentration. In addition, an F-test was used for the estimation of EC 50 values obtained from best-fit analysis using a nonlinear interactive fitting program for ACh and PE (GraphPad Prism, Graph Pad Software Inc.; San Diego, CA). Other parameters were analyzed using Student's t-test for significance. Data are expressed as means ± S.E.M. (n), where 'n' is the number of mice. Values of P < 0.05 were considered statistically significantly different.
Results
Effect of diabetes on body weight and blood glucose
Compared to age-matched control mice, diabetic mice exhibited a significant decrease in body weight (27.86 g ± 0.53 in vehicle vs 23.25 g ± 0.29 in STZ; P < 0.05). As expected, STZ injections resulted in significant increases in blood glucose levels compared to vehicleinjected mice (136.7 mg/dl ± 4.2 in vehicle vs 489.4 mg/dl ± 13.1 in STZ; P < 0.05).
Effect of diabetes on contraction and relaxation
There was no significant difference in relaxation to ACh (70.6% ± 2.9 in vehicle vs 65.6 ± 2 in STZ at 10 -6 M; P = 0.16) and contraction to50 mM KCl (0.50 g ± 0.04 in vehicle vs 0.56 ± 0.002 in STZ; P = 0.12). However, aortas isolated from diabetic mice exhibited a significant increase in contractility to the α1-adrenergic receptor agonist PE (91.4% ± 1.9 in vehicle vs 105.9% ± 3.5 in STZ at 10 -6 M; P < 0.05) (Fig. 1) .
3.3. Aortas from diabetic mice exhibited decreased contraction to A 1 adenosine receptor activation A 1 adenosine receptor activation resulted in a dose-dependent increase in aortic contraction; however, aortas from STZ-treated mice exhibited a significant decrease in A 1 adenosine receptor-mediated contraction to CCPA when compared to vehicle (Fig. 2) . Conversely, A 3 adenosine receptor contraction to its agonist, Cl-IBEMCA, was not different between aortic rings isolated from vehicle or diabetic mice (Fig. 2) . Although aortas isolated from vehicle-treated mice tended to have an increased relaxation to A 2A adenosine receptor agonist CGS at high concentrations (10 -6 and 10 -5 M), it was not significantly different between the aortas isolated from vehicle-and STZ-treated mice (P = 0.19 and P = 0.17, respectively; Fig. 2 ). In addition, relaxation to the A 2B adenosine receptor agonist BAY was not different between the two groups (Fig. 2) .
3.4. Aortas from diabetic mice exhibited increased contraction to α1-adrenergic receptor activation
While we did not see a significant difference in endotheliummediated vasorelaxation to ACh between aortas from vehicle-and STZtreated mice (EC50: 7.06 ± 0.09 in vehicle vs 6.88 ± 0.09 inSTZ; P > 0.05; Fig. 3 ), the aortas from STZ-treated mice exhibited a significant increase in contraction to the α1-adrenergic receptor agonist PE (EC 50 : 6.89 ± 0.14 in vehicle vs 7.40 ± 0.08 in STZ; P < 0.05; Fig. 3 ).
Mesenteric artery responses to adenosine receptor activation were not affected by diabetes
The mesenteric vascular response to adenosine receptor activation with the adenosine receptor agonists CCPA (A 1 adenosine receptor), Cl-IBEMCA(A 3 adenosine receptor), and BAY (A 2B adenosine receptor) were not different between vehicle-and STZ-treated mice (Fig. 4) . Previous studies from our laboratory have shown that A 2A adenosine receptor activation does not affect vascular tone in mesenteric arteries (Teng et al., 2013) .
Mesenteric artery contraction responses to PE were not different between the two groups (251.3% ± 34.9 KCl contraction in vehicle vs 265.4% ± 53.9 KCl contraction in STZ; n = 10; P > 0.05, data not shown). To investigate whether diabetes affects endothelium-mediated vasorelaxation in diabetic mesenteric arteries, CRC to ACh was performed. ACh-mediated vasorelaxation in mesenteric arteries isolated from diabetic mice was not different from that of control mice (EC 50 : 7.34 ± 0.17 in vehicle vs 7.62 ± 0.21 in STZ, data not shown).
Aortic A 1 adenosine receptor protein expression was not affected by diabetes
Since diabetes affects aortic responses to A 1 adenosine receptors, we looked at the expression of A 1 adenosine receptor. A 1 adenosine receptor expression in aortas isolated from diabetic mice was not significantly different from that of the vehicle-treated mice (Fig. 5) .
Discussion
In the present study, we aimed to elucidate the contribution of adenosine receptors to vascular tone in mice with T1D. We showed that diabetes resulted in decreased A 1 adenosine receptor-mediated contraction in the aorta, which was accompanied by increased aortic contraction to PE. However, A 1 adenosine receptor-mediated responses in mesenteric arteries were not different between vehicle-and STZtreated mice, suggesting a differential vascular bed effect of diabetes on adenosine receptor function. Interestingly, A 1 adenosine receptor expression in the aorta was not different between the two groups, suggesting a possibly decreased sensitivity of A 1 adenosine receptor to its agonist in the aortas of diabetic mice. Our results are in concordance with earlier studies showing that, in STZ-treated diabetic rats, there was a decrease in A 1 adenosine receptor sensitivity to adenosine and impaired Gi coupling, with no change in A 1 adenosine receptor expression in adipocytes (Barrington et al., 1996; Green and Johnson, 1991) . Furthermore, T1D had a tissue-specific effect on A 1 adenosine receptor sensitivity (Barrington et al., 1996) , which may be the case in the present study as we did not see a difference in response to A 1 adenosine receptor activation in mesenteric arteries, contrary to aortas. The disconnect between the expression and activity/signaling of adenosine receptors is not novel. In fact, our laboratory has previously shown that, while mesenteric arteries express A 2A adenosine receptor, this adenosine receptor subtype does not contribute to the regulation of their vascular tone (Teng et al., 2013) . Also, another study showed that, while the coronary arteries express A 2B adenosine receptor, this receptor did not play an active role in the endogenous regulation of coronary blood flow (Berwick et al., 2010) . Interestingly, the same group demonstrated that obesity and metabolic syndrome augmented the contribution of A 2B adenosine receptor to adenosine-induced dilation, which was surprisingly associated with a decrease in coronary A 2B adenosine receptor protein expression (Bender et al., 2009 ). Together, these data, with other studies, suggest that diseases such as diabetes may alter receptor sensitivity and/or signaling independent of receptor expression levels. Unfortunately, little is known about the posttranslational modifications of adenosine receptors during both healthy and disease conditions, as is how these modifications (such as O-linked Nacetylglucosamineprotein modification in diabetes) may affect the receptor's intracellular signaling pathways and activity (Palmer and Stiles, 1999) . As expected, STZ treatment resulted in an increase in blood glucose levels, accompanied by a significant decrease in body weight. These effects have been well documented by our laboratory and many others (Grden et al., , 2007 Labazi et al., 2016a; Pawelczyk et al., 2005) . While we did not observe differences in endothelium-mediated vasorelaxation in aortas and mesenteric arteries from vehicle-and STZtreated groups, contractile responses to the adrenergic receptor agonist PE was significantly higher in aortas from diabetic mice. These data are in concordance with previous studies (Rehman et al., 2014; Xie et al., 2010) . The observed decreased contraction to the A 1 adenosine receptor agonist may also be a compensatory mechanism to counteract increased aortic contractility to other agonists, such as PE, in diabetes to regulate vascular tone, at least at this early stage of T1D.
The newly considered notion that adenosine levels and adenosine receptor expression are dramatically changed in pathological conditions allowed for a new proposed role for the adenosine receptors. However, our understanding of the contribution of adenosine receptors to the physiology and pathophysiology of the cardiovascular system is still at an early stage, and the findings in the field seemed contradictory. For instance, increased adenosine levels and activation of A 2B adenosine receptor signaling was shown to be protective during diabetic nephropathy (Tak et al., 2014) . However, increased adenosine and expression of A 2B adenosine receptor was shown to contribute to hypertension in chronic kidney disease (Zhang et al., 2013) . This contradictory role of elevated adenosine levels and A 2B adenosine receptor signaling can be explained by the fact that A 2B adenosine receptor signaling can be tissue specific (endothelial cells vs whole kidney) or disease specific (diabetes vs hypertension). In addition, adenosine receptor signaling pathways are still under investigation.
In the vasculature, it is known that A 2A and A 2B adenosine receptors are stimulatory for adenylyl-cyclase, leading to cyclic-AMP (cAMP) production and vasodilation, while the A 1 and A 3 adenosine receptors are linked to the inhibitory G i , suppressing adenylyl-cyclase and favoring contraction. However, studies have shown that pathways associated with increased vascular contraction, such as PKC and MAPK, can also be activated by A 2A and A 2B adenosine receptors. This was shown to be independent of Gs and was dependent upon Gi or Gq activation (Cohen et al., 2010; Schulte and Fredholm, 2003) . The ability of theses receptors to potentially trigger multiple signaling pathways is intriguing and raises the question of if these signaling pathways are tissue specific and whether disease states, such as hypertension or diabetes, can favor one pathway over another. This may also explain the contradictory role of these receptors in attenuating versus exacerbating the disease (Tak et al., 2014; Zhang et al., 2013) . Thus, it is imperative to study adenosine signaling in disease states to understand their contribution to the amelioration or exacerbation of the disease.
In an STZ-treated animal model,A 1 adenosine receptor expression was increased in the kidney , while its expression in pancreatic α-cells was diminished in a non obese diabetic mouse model (Yip et al., 2013) , suggesting that its expression may be affected in diabetes. In the present study, we did not see a difference in A 1 adenosine receptor expression in the aorta, although the vascular response to A 1 adenosine receptor agonist was attenuated in aortic rings from diabetic mice. This may be a result of altered A 1 adenosine receptor signaling through decreased A 1 adenosine receptor sensitivity to its agonist or its coupling to Gi, which was shown to be impaired in T1D (Barrington et al., 1996; Green and Johnson, 1991) . In addition, T1D was shown to be associated with a decreased expression of Gi in rat hepatocytes, which may also result in decreased A 1 adenosine receptor signaling (Gawler et al., 1987) . In addition, posttranslational modifications that are associated with diabetes, such as O-Glc-N-acylation, may also affect receptor signaling.
Conclusion
Other studies have shown that, despite apparent vascular dysfunction, blood pressure in STZ-treated animals is not significantly different from that of control animals (Nacci et al., 2009; Tojo et al., 2016) . In this study, we showed that vascular A 1 adenosine receptor signaling was reduced in diabetes, and this may be due to a compensatory mechanism to counteract increased vascular contractility observed in diabetes and prevent increases in blood pressure (see Fig. 6 ). Our present study also showed a disconnect between receptor expression and signaling, which has also been previously shown by others (Bender et al., 2009) . Thus, future studies investigating post-translational modifications and/or downstream receptor signaling pathways are crucial to understanding the potential role of the A 1 adenosine receptor and may explain the discrepancy observed between adenosine receptor expression and signaling in cardiovascular physiology and pathophysiology.
